All Industries

Wolfpack Financial Has A Plan To Help Millennials And Gen Z Attain Their American Dream

Benzinga

By Anthony Termini, Benzinga Many Americans aged 18 to 27 either still live with their parents or rely on them for some financial support, according to a recent survey conducted by Bank of America. Tax and accounting consultants, Ernst & Young point out in a similar survey that more than half of GenZers say they are worried about not having enough money. In 2021 an article on the HuffPost website, explained how "millennials are facing the scariest financial future of any generation since the Great Depression." Prior to that, The Wall Street Journal conducted a survey that found "more than half of millennials surveyed feel overwhelmed by financial obligations." Their survey also noted that they don’t trust traditional financial institutions. Layered atop these sentiments is the reality that the way Americans earn a living is changing. According to management consultants McKinsey & Company, in 2022, some 58 million Americans identified themselves as independent (or gig) workers. TechReport.com notes that “over two-thirds of full-time gig workers find it a more secure form of employment than a regular job.” All of this seems to support what think tank New America, has reported. They found that in general, "Americans believe the American Dream… is becoming more difficult to attain." Amid such a landscape, one company may offer Millennials and Gen Zers a reason to feel optimistic about their financial futures. Wolfpack Financial Is Poised To Roll Out A Novel Approach To Investing Wolfpack Financial is a native app investment company focused on helping Millennials and Gen Zers control their finances and build generational wealth. The company, incorporated in Delaware with headquarters in New York, is not a traditional brokerage. Wolfpack offers an investment opportunity with multiple benefits for beginning and inexperienced investors. For example, the app makes it possible for an investor to open an account with a minimum of $5. What’s more, Wolfpack offers up to $50 in rewards to new customers meeting certain conditions who download the mobile app and fund their accounts with a minimum of $100. These same customers also automatically receive pre-approval for up to $2,000 in “Booster Loans” and priority access to them when they are launched later this year. Wolfpack’s Booster Loan program is one of the features that makes the app unique and particularly beneficial for the young customer base the company caters to. Booster Loans are a type of lending product that gives investors an opportunity to augment their cash purchases. The patent-pending innovation is a Buy-Now-Pay-Later system for buying stocks and ETFs. Wolfpack’s technology allows a customer to use smart leverage to purchase assets and then pay back the borrowed funds over a fixed 10-week repayment schedule. Booster Loans make it possible for an investor with $100 cash to invest up to $200 in a stock or ETF. Individual Wolfpack customers enjoy this unique investment opportunity, and the company also has an enterprise version it intends to license to banks and brokerage firms that don’t have a similar offering or functionality. Wolfpack notes that more than 90% of such U.S. institutions fall into that category, which results in cash outflows to other companies that do provide those services. Booster Loans are the only fully collateralized Buy-Now-Pay-Later lending product on the market, says Wolfpack, and the company will use it to help its strategic partners be more competitive with firms like Robinhood Markets (NASDAQ: HOOD) or WeBull. Another factor that makes Wolfpack unique in the industry is that there are no penalties for consumers using the Wolfpack app. The company also offers commission-free trades and fractional share trading and lets investors buy securities for as little as $5.00 per trade. Wolfpack prides itself on its product, noting that Booster Loans are a better alternative to personal loans, credit cards and traditional margin lending because of its lower interest rate. Why Millennials And Gen Zers May Want To Begin Their Investment Journeys Now While the financial stress felt by Millennials and Gen Zers is real, there is still much for them to be optimistic about. Collectively, they stand to benefit from one of the greatest wealth transfers in history. Some $84 trillion is expected to be inherited by these Americans in the next 20 years – about $16 trillion of that will be transferred in the next decade. Wolfpack believes that an important part of being able to manage that future wealth can be gained from the investment experience and education it offers to the current generation of beginning and inexperienced investors. These may be some of the greatest benefits Wolfpack users get from the app. Investment information about Wolfpack is available on the Wefunder website, and those interested in the Rewards and Priority Access being offered to new account holders should visit the company’s website. Featured photo by Nattanan Kanchanaprat from Pixabay. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

August 26, 2024 08:50 AM Eastern Daylight Time

Image

Theriva Biologics Receives Rare Pediatric Drug Designation From FDA For Treatment Of Retinoblastoma

Benzinga

By Kyle Anthony, Benzinga The growing prevalence of cancer is not limited to adults; it is also afflicting children. An estimated 15,780 children between birth and 19 years of age are diagnosed with cancer each year in the U.S., according to the American Childhood Cancer Organization. Approximately 1 in 285 children in the U.S. will be diagnosed with cancer before their 20th birthday. Globally, there are more than 300,000 children diagnosed with cancer each year, and the rate of childhood cancer is slowly rising; cancer cases increased to 177 per million in 2019 from 165 per million in 2003. Recently, Theriva Biologics (AMEX: TOVX), the clinical-stage immuno-oncology company developing therapies for difficult-to-treat cancers, was granted Rare Pediatric Drug Designation (RPDD) by the U.S. Food and Drug Administration (FDA) for VCN-01 for the treatment of retinoblastoma; the most common type of eye cancer in children. Retinoblastoma Presents Significant Treatment Challenges Retinoblastoma is a tumor that originates in the retina and accounts for approximately 2% of all childhood cancers. Some 200 to 300 children are diagnosed each year in the U.S., and the cancer is most common among infants and young children. The average age of a child when diagnosed is two years of age. Approximately three out of four children with retinoblastoma have a tumor in only one eye (known as unilateral retinoblastoma). When both eyes are affected it is known as bilateral retinoblastoma. Although the chances of developing retinoblastoma are statistically low, the challenge of preserving life while preventing the loss of an eye, blindness, and other severe consequences that diminish both lifespan and quality of life remains significant. Furthermore, in low-resource countries, children with retinoblastoma face a higher risk of losing their eyes and succumbing to metastatic disease. Recently, market research and industry consulting firm Spherical Insights assessed the global retinoblastoma treatment market size to be $2.5 billion in 2023; and it is expected to grow to $3.8 billion by 2033. Rare Pediatric Drug Designation For VCN-01 As the name suggests, the Rare Pediatric Drug Designation is a special status given to drugs explicitly developed for treating rare diseases that affect children. This designation is part of a broader effort to encourage the development of medications for conditions not commonly addressed due to the small number of patients, particularly in the pediatric population. For Theriva Biologics, this designation comes with a key incentive: if a Biologics License Application for VCN-01 for the treatment of retinoblastoma is approved by the FDA, Theriva says it may be eligible to receive a Priority Review Voucher (PRV) that can be redeemed to receive a priority review for any subsequent marketing application or may be transferred or sold. PRVs have previously been sold by different companies for around $100M. “The FDA’s decision to grant rare pediatric drug designation to VCN-01 highlights the urgent need for new treatment options for pediatric patients with retinoblastoma. We are encouraged by this important step forward and, in parallel, continue to work closely with leading physicians and regulatory agencies to refine our clinical strategy for VCN-01 as an adjunct to chemotherapy in pediatric patients with advanced retinoblastoma,” said Steven A. Shallcross, CEO of Theriva Biologics. “Most recently, results from the investigator-sponsored Phase 1 trial evaluating the safety and activity of intravitreal VCN-01 in pediatric patients with refractory retinoblastoma were determined to be positive by the study Monitoring Committee. Data from this study will further inform our clinical development pathway in this area of high unmet need,” he said. With VCN-01 receiving RPDD from the U.S. FDA, this milestone speaks to the drug's efficacy and long-run potential. As such, the social benefit that Theriva Biologics provides could continue to grow and have increased industry resonance. Featured photo by Ani Kolleshi on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

August 26, 2024 08:45 AM Eastern Daylight Time

Image

Poster Presentations, Upcoming Human Trials, Recently Secured Funding And More: Glucotrack’s Plans To Transform The Continuous Glucose Monitoring Market

Benzinga

By Meg Flippin, Benzinga Managing diabetes has gotten an overhaul thanks to continuous glucose monitoring devices (CGM). Glucotrack Inc. (NASDAQ: GCTK), the Rutherford, New Jersey medical technology company that makes a continuous blood glucose monitoring (CBGM) device, is seeking to position itself to transform the glucose monitoring market. It is doing so through what it says is a game-changing medical technology that overcomes the challenges of the existing devices on the market, including the lack of real-time accuracy, the need for frequent sensor changes and concerns regarding comfort and wearability. Glucotrack’s implantable Continuous Blood Glucose Monitor (CBGM) measures glucose in the blood, something no other known competitor is offering to date. By measuring glucose in the blood instead of glucose in interstitial fluids – which is what most other devices measure – users get an accurate, real-time reading. Plus, Glucotrack’s implant can last up to three years, compared to less than one year for many of the continuous glucose monitoring (CGM) devices on the market. Patients don’t have to worry about sticking an adhesive to their body or be concerned about it falling off during physical activity, whether it's swimming or hot yoga. The CBGM, which also requires minimal calibration, eliminates the hassle and discomfort of a wearable that requires frequent replacement, the company said. Making The Rounds Glucotrack has been busy getting the word out about the potential of its CBGM. In June, it presented two posters at the American Diabetes Association (ADA) 84th Scientific Sessions discussing preclinical animal studies and a sensor longevity simulation modeling for its CBGM. The ADA Scientific Sessions is one of the premier diabetes conferences which provides a platform for the latest advancements in diabetes research, prevention and care. This annual meeting provides researchers and healthcare professionals with the opportunity to share ideas and learn about cutting-edge technologies and breakthroughs in diabetes research and diabetes-related conditions. Glucotrack also presented an emerging science industry poster at the Association of Diabetes Care and Education Specialists annual conference, which took place from Aug. 9 to 12. The poster presented market research data on the acceptance of the company’s CBGM concept among people with type 1 and type 2 diabetes. It highlighted that out of 757 respondents with type 1 and type 2 diabetes using a variety of insulin regimens, there was a positive sentiment towards the CBGM concept, with over 50% of potential users open to adopting the product. In other words, the CBGM concept could be a viable alternative to existing products on the market. PreClinical Trials In The Bag Glucotrack’s data so far seems to back up its claims, including its recent 90-day preclinical study demonstrating the sustained accuracy of its CBGM. The second long-term preclinical study for its CBGM showed a Mean Absolute Relative Difference (MARD) of 4.7% at day 90, which is considered highly accurate for a continuous glucose monitor, reports Glucotrack. MARD is a key metric used to assess the accuracy of glucose monitoring devices, measuring the average difference between the CBGM device’s measurement and a reference measurement, most often obtained via capillary blood glucose. Lower values indicate better performance, said Glucotrack. The company said the 90-day preclinical study, which included a larger number of animal subjects and a longer duration than the initial 60-day study announced earlier this year, further validates the CBGM’s sustained accuracy and performance. “We are again very pleased with the performance of our sensor during a long-term preclinical study and look forward to moving into human clinical trials,” stated Paul Goode, PhD, president and CEO of Glucotrack. “Our CBGM’s ability to continuously measure blood glucose for 3 years with accuracy, minimal calibration and without a wearable device represents a significant advancement in glucose monitoring. We believe this technology has the potential to greatly improve the quality of life for people with diabetes by providing a more convenient and discreet monitoring solution,” he said. Cashing In All of these developments seem to have brought Glucotrack investment money; in July, the company secured $4 million in funding from its leading shareholder to support its upcoming first in-human clinical trial. It also helps the company that it has a deep leadership bench and board with years of experience. Take Goode, for starters. He has decades of experience developing innovative medical technologies in the implantables and glucose monitoring space for big-name medical technology companies, including DexCom Inc. (NASDAQ: DXCM), a global continuous glucose monitoring company. Goode is a named inventor on over 150 issued patents, including over 100 relating to Dexcom’s continuous glucose sensing technology. Meanwhile, Mark Tapsak, Ph.D., VP of Sensor Technology, has held senior positions at diabetes management companies, including as senior scientist at DexCom. Further, the bench just got deeper with the appointment of Andy Balo – a former DexCom executive – to the board. Balo brings decades of regulatory, clinical and quality experience in the medical technology industry. In 2002, he joined DexCom as part of the original executive team where he remained for the next 22 years, playing a key role in shaping the company’s future. During his tenure, he was responsible for numerous glucose monitoring regulatory submissions and clinical trials worldwide, and coordinated quality activities across multiple manufacturing facilities. With a forecasted CAGR of 10.3% over 2024-2034, the continuous glucose monitoring market could be poised to take off, and Glucotrack wants to play a role in expanding options for patients with its technology. With preclinical trials already being in the bag, and human trials up next - the company feels its commitment to that goal is progressing steadily toward fruition. Featured photo by Mykenzie Johnson on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

August 26, 2024 08:30 AM Eastern Daylight Time

Image

News Release

Core X Solutions, Headed by Hani Saleh, Introduces Innovative Gift Card and Voucher Service

Rev Up Marketers

Core X Solutions is proud to introduce a groundbreaking new service under the leadership of Hani Saleh, CEO and Co-Founder. This innovative platform is set to transform the way consumers and businesses acquire and resell gift cards and vouchers, offering unprecedented convenience, value, and integration capabilities. The new service leverages Core X’s advanced technology to aggregate gift cards and vouchers from multiple reliable sources. This ensures a wide range of options, allowing users to find exactly what they need at the most competitive prices available. Whether you're a consumer looking for a specific gift card or a business aiming to resell vouchers, Core X’s platform guarantees the best deals on the market. Core X Solutions stands out with its best price guarantee. By sourcing from various providers, the platform ensures that both individual consumers and businesses receive the lowest possible prices. This applies equally to end-users purchasing for personal use and businesses integrating the service via API for resale purposes. The service is particularly beneficial for businesses, offering a powerful API that facilitates seamless integration into their existing systems. This feature empowers businesses to easily resell gift cards and vouchers, thus opening up new revenue streams. The API is designed for efficiency, helping businesses reduce operational costs while enhancing their service offerings. Hani Saleh, the visionary behind Core X Solutions, commented on the launch: “Our new gift card and voucher service is a testament to our commitment to innovation and delivering exceptional value to our customers. By aggregating multiple sources and ensuring the best prices, we are simplifying the process for consumers and empowering businesses to thrive. This launch marks a significant step forward in our mission to enhance user experience and support business growth.” The launch of this service comes at a crucial time when both consumers and businesses are looking for more efficient and cost-effective ways to manage gift card and voucher transactions. By combining a user-friendly interface with powerful backend integration, Core X Solutions is positioned to become a leader in this space, providing a service that is not only reliable but also adds tangible value to its users. About Core X Solutions: Core X Solutions continues to lead the industry in providing innovative self-service and business optimization solutions. With a focus on quality, innovation, and customer satisfaction, the company is committed to driving growth and efficiency for businesses worldwide. For more information about the new gift card and voucher service, and to explore how it can benefit you or your business, visit Core X Solutions. Contact Details Core X Solutions Mr. Hani Saleh info@corex.solution Company Website https://corex.solutions/

August 26, 2024 06:51 AM Eastern Daylight Time

Hove Capital Management Explores Potential Strategic Partnerships with BNP Paribas and Société Générale”

Pinion Newswire

Hove Capital Management, a leading force in the fixed rate bond market with over 20 years of industry expertise, is seeking new strategic alliances with two of Europe’s foremost financial institutions: BNP Paribas and Société Générale. These collaborations will mark a significant milestone in Hove Capital Management’s mission to enhance its service offerings and extend its global presence. These potential partnerships underscore Hove Capital Management’s commitment to leveraging collective strengths to drive innovation, improve client services, and deliver superior financial products tailored to the evolving market landscape. “We are pleased to announce that, after much deliberation, The Banque de France has granted its approval, allowing these partnerships to proceed,” said Richard O’Brien, Senior Partner at Hove Capital Management. “This approval is a crucial step, and its receipt has paved the way for our collaborations with BNP Paribas and Société Générale to move forward. We are excited about the new opportunities this approval unlocks and its positive impact on our ability to serve our clients more effectively.” The collaboration with BNP Paribas and Société Générale will enable Hove Capital Management to deepen its market engagement and reinforce its presence across pivotal financial hubs in Europe. This potential expansion aims to harness local expertise and insights crucial for navigating regional market complexities. The partnerships will also enhance Hove Capital Management’s analytical capabilities and provide a broader perspective on global economic trends. “Entering into these collaborations allows us to share knowledge, risk management strategies, and resources, positioning us to meet our clients’ financial goals better,” added Richard O’Brien. “We are particularly excited about the potential these partnerships have to advance our analytical capabilities and broaden our understanding of global economic trends.” Hove Capital Management has meticulously planned these collaborations to align with its core values and long-term objectives. The company remains focused on its mission to deliver high-quality, customized bond brokerage services by continuously adapting to market needs and enhancing operational efficiency. Hove Capital Management anticipates that these strategic partnerships will not only strengthen its market position but also foster innovation within the fixed-rate bond sector. For the latest updates and more information about Hove Capital Management and its services, please visit hovecapitalmanagement.com Contact Details Hove Capital Management Peter Nobel +1 917-601-3863 p.nobel@hovecapitalmanagement.com Company Website https://hovecapitalmanagement.com/

August 23, 2024 01:16 PM Eastern Daylight Time

RedHill's Opaganib Shows Diabetes And Obesity Potential With Positive In Vivo Results

Benzinga

By Meg Flippin, Benzinga A potential, previously unexplored pathway for fighting diabetes and obesity-related disorders may have been unveiled by RedHill Biopharma (NASDAQ: RDHL), a specialty biopharmaceutical company, and its partner Apogee Biotechnology Corp., who are busy developing what may be an interesting new approach in the obesity and diabetes market. The company is testing opaganib in a range of metabolic disease models designed to show its potential to prevent and treat type 2 diabetes and other obesity-related diseases and recently received positive in vivo results. The positive results of early trials are good news for RedHill Biopharma given the global obesity-diabetes drug market opportunity is huge, projected to reach $100 billion by 2030. It’s being driven largely by Glucagon-like peptide-1 (GLP-1) inhibitors like Novo Nordisk’s (NYSE: NVO) Ozempic and Wegovy (semaglutide), Eli Lilly’s (NYSE: LLY) Trulicity (dulaglutide) and Mounjaro (tirzepatide) and sodium glucose cotransporter-2 (SGLT2) inhibitors such as Boehringer Ingelheim’s Jardiance (Empagliflozin), reports RedHill. If RedHill is right about opaganib, it could join those ranks. “Sphingolipid metabolism is implicated in insulin resistance, β-cell disruption, adipocyte function, inflammation and immune regulation, vascular complications and energy metabolism – all significant components of obesity, diabetes and their associated complications,” said Charles D. Smith, Ph.D. Founder and CEO of Apogee Biotechnology Corp., Redhill’s partner who led the testing of opaganib for the treatment and prevention of type 2 diabetes and other obesity-related disorders. “Opaganib’s ability to modulate multiple signaling pathways through simultaneous inhibition of three sphingolipid-metabolizing enzymes in human cells provides a strong rationale for evaluation of opaganib in obesity-related disorders.” Opaganib Slows Weight Gain Earlier this week RedHill announced that in vivo studies conducted by RedHill’s partner, Apogee, yielded positive results. The studies looked at the impact opaganib had on weight gain and glucose tolerance in a high-fat diet (HFD) model. They demonstrated opaganib suppressed HFD-induced body weight gain, loss of glucose tolerance and fat deposition. Additionally, opaganib reduced weight gain and restored glucose tolerance in an already obese HFD model, suggesting its potential for treating, not just preventing, obesity-related disorders, reports RedHill Biopharma. “Sphingolipid metabolism is a key pathway in many diseases, including obesity, but has not been adequately examined as a therapeutic target for human therapy,” said Dr. Mark Levitt, Chief Scientific Officer at RedHill. “Opaganib, which acts as a sphingosine competitor, is the first clinical drug to target three key enzymes in this pathway.” With multiple U.S. government collaborations ongoing, opaganib, RedHill Biopharma’s first-in-class new chemical entity with anti-inflammatory, anti-cancer and antiviral activity, is a host-directed, potentially broad-acting, orally administered small molecule drug with demonstrated safety & efficacy profiles. It is in development for multiple oncology, viral, inflammatory and diabetes and obesity-related indications, including COVID-19, Ebola, acute respiratory distress syndrome (ARDS) and radio/chemical protection. More Than Fighting Diabetes But it’s not just in fighting diabetes and obesity-related disorders where RedHill is making progress. Adding to its commercialization by RedHill in the U.S., the company just launched Talicia (omeprazole magnesium, amoxicillin and rifabutin) in the United Arab Emirates (UAE) – making it available by prescription to treat adults with Helicobacter pylori ( H. pylori ) infection. Talicia is the first approved low-dose rifabutin-containing all-in-one combination product in the UAE specifically designed to treat H. pylori. The commercial launch of Talicia in the UAE triggers RedHill’s eligibility for additional potential milestone payments, minimum sales payments and tiered royalties up to mid-teens on net sales. Talicia is a novel, fixed-dose, all-in-one oral capsule combination of two antibiotics (amoxicillin and rifabutin) and a proton pump inhibitor (PPI) (omeprazole). In November 2019, Talicia was approved by the U.S. FDA for the treatment of H. pylori infection in adults. In a pivotal Phase 3 study, Talicia demonstrated 84% eradication of H. pylori infection in the intent-to-treat (ITT) group vs. 58% in the active comparator arm (p<0.0001). “As one of the strongest risk factors for gastric cancer, H. pylori is a major public health concern,” said Rick Scruggs, President & Chief Commercial Officer at RedHill. “With 41% of the UAE population infected by H. pylori and the alarming failure rates of clarithromycin-based therapies, there is a significant medical need for a highly effective first-line H. pylori therapy. Our efforts to make Talicia available to patients in more countries continue as we work to explore additional opportunities with existing and potential partners.” From preventing diabetes and obesity-related diseases to fighting H. pylori, RedHill Biopharma seems to be making strides with its key drug compounds. Early testing shows promise, potentially making this a company worth watching. To learn more about RedHill Biopharma’s pipeline, click here. Featured photo by Diana Polekhina on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

August 23, 2024 08:30 AM Eastern Daylight Time

Image

Communication Service for the Deaf Appoints Brendan Gramer and Roberta Mather to Board of Directors

Communication Service for the Deaf

Communication Service for the Deaf (CSD), a nonprofit organization dedicated to empowering the lives of Deaf and hard of hearing individuals, proudly announces the appointment of two new board members, Brendan Gramer and Roberta Mather. Brendan Gramer joins the board with a distinguished career at Amazon, where he serves as UX Design Manager on the Payments team, contributing his expertise for 16 years. Known for his impactful advocacy for accessible design, Brendan has been instrumental within Amazon’s internal Design Tools & Resources Working Group and AUX (Accessibility to the UX Design Community). His leadership also extended to encouraging Deaf representation in accessibility, diversity, and inclusion initiatives, including his recent tenure as Global President of AmazonPwD (People with Disabilities) affinity group. "I am honored to join CSD’s Board of Directors," said Brendan Gramer. "Throughout my journey, I’ve been passionate about breaking down barriers, pushing for access, and promoting inclusivity. I look forward to contributing to CSD’s mission of supporting the Deaf community." Brendan Gramer’s commitment to advocacy extends beyond his professional endeavors. He holds various volunteer leadership roles, including the Hearing Loss Advisory Council of the Washington Office of the Deaf and Hard of Hearing, Deaf Kids Code, United Airlines Accessible Travel Advisory Board, and the Deaf Thrive Steering Committee. Born profoundly deaf in Chicago, Brendan grew up using oral communication and later learned American Sign Language (ASL). He resides in Seattle with his Deaf wife and sons, leveraging his personal experiences to drive positive change for the Deaf community. Roberta Mather brings a wealth of experience and impressive career as a leader, especially as a civil servant in International Relations with 20+ years of experience in diplomacy. Previously, Mather served as the Senior Advisor for Employee Communications with the U.S. Department of State, overseeing messaging to a workforce of over 75,000 employees worldwide. Further, she has decades’ worth of marketing, graphic design, printing, and branding. She is recognized internationally for her expertise in Diversity of Thought, global equity, and the power of storytelling in driving policy and advocacy initiatives. On the side, Roberta is passionate about community service, paying it forward through non-profit events that celebrate the community and create memories. “CSD is a beacon of the Deaf and inclusive entrepreneurship. I look forward to joining the board only to serve behind the scenes, witnessing innovation propel into the 22 nd century in our lifetime.” Said Mather. "We are thrilled to welcome Brendan Gramer and Roberta Mather to our board," said CSD’s CEO Christopher Soukup. "Brendan’s expertise in accessible design and Roberta’s track record and deep commitment to effective communication will greatly enrich our board’s leadership as we continue to advocate for greater accessibility and inclusion.” For more information about CSD and its new board members, visit csd.org/about. About Communication Service for the Deaf Communication Service for the Deaf (CSD) is the largest Deaf-led social impact organization in the world. For more than four decades, CSD has been a leader in creating and providing accessible and innovative solutions for the Deaf community. Today, CSD continues its work to create opportunities for personal and economic growth within the Deaf community, specifically addressing leadership and employment. For more information, please visit CSD and follow us on Facebook, Twitter, Instagram, and LinkedIn. Contact Details Maria Wilson mwilson@csd.org Company Website https://www.csd.org/

August 23, 2024 08:00 AM Eastern Daylight Time

News Release

Vending Venue LTD Launches Pizza Vending Machines Across the UK

Rev Up Marketers

Vending Venue LTD is introducing a groundbreaking innovation in the fast food industry with the launch of its pizza vending machines, now available for sale across the UK. This development offers a fresh, hot meal option accessible at any time, catering to both urban and suburban areas where traditional food outlets may be less accessible or convenient. The pizza vending machine for sale UK is set to transform how consumers access fast food, providing a reliable and efficient solution that aligns with the demands of modern life. The pizza vending machines for sale by Vending Venue LTD are designed to meet the growing need for quick and convenient food service without compromising quality. Each machine is equipped with state-of-the-art technology that allows it to prepare, cook, and dispense a variety of pizzas on demand. This includes mixing the dough, adding toppings, and baking the pizza in a specialized oven. The result is a freshly made pizza that is ready in just a few minutes, offering consumers a satisfying meal option that is available 24/7. These machines are not just about convenience; they also represent a significant advancement in the fast food industry. By providing a consistent product in a compact and efficient format, the pizza vending machines for sale UK are poised to become a staple in locations where traditional food outlets may not operate around the clock. This includes high-traffic areas such as airports, shopping centers, universities, and even residential neighborhoods, where the demand for fresh, hot food at all hours is growing. Vending Venue LTD specializes in providing innovative vending solutions that cater to the evolving needs of consumers. The introduction of these pizza vending machines is a clear example of how technology can be harnessed to meet the demand for fast, reliable, and high-quality food service. The machines are designed with the user in mind, featuring a simple and intuitive touchscreen interface that guides customers through the ordering process. Payment options include cash, credit cards, and contactless methods, ensuring accessibility for a wide range of users. The pizza vending machine for sale UK also offers significant benefits for businesses looking to capitalize on the trend toward automated food service. These machines require minimal maintenance, and their robust design ensures reliable operation even in high-traffic areas. Remote monitoring capabilities allow operators to track sales, monitor inventory, and receive alerts for maintenance needs, all from a distance. This makes the machines not only a convenient option for consumers but also a profitable investment for entrepreneurs and businesses. The introduction of pizza vending machines for sale represents a shift in the fast food industry, where the focus is increasingly on convenience, quality, and accessibility. Vending Venue LTD is at the forefront of this movement, providing solutions that meet both consumer and business needs. The ability to deliver freshly baked pizzas at any time of day or night positions these vending machines as a viable alternative to traditional food outlets, especially in areas where such options are limited. As the demand for convenient and high-quality food options continues to grow, the pizza vending machine for sale UK by Vending Venue LTD is set to play a pivotal role in the future of fast food service. By combining advanced technology with practical applications, these machines offer a new way for consumers to enjoy a restaurant-quality meal in minutes, regardless of the time or place. For more information about the pizza vending machine for sale UK and other vending solutions, visit Vending Venue LTD. Contact Details Vending Venue LTD Jordyn Jones sales@vendinvenue.com Company Website https://vendinvenue.com/

August 23, 2024 06:59 AM Eastern Daylight Time

News Release

Sector Spotlight: Top 4 Basket of Diagnostic Stocks (EXAS, GH, ILMN, LUDG)

LUDG EXAS GH ILMN

Big diagnostic companies soared during the pandemic thanks in part to mandated government testing, but once the at-home kits arrived and insurance companies were forced to foot the bill, diagnostic companies with COVID-19 revenues collapsed. Many diagnostic companies got caught in the downdraft because they thought the testing gravy train was going to continue and ramped up capacity instead of diversifying. The opportunity in the sector comes from diagnostic companies that chose to reinvent themselves by developing early cancer screening tests. During the pandemic, regular cancer screenings were put off to conserve medical resources toward COVID. Since the pandemic is over, it's worth reexamining beat-up diagnostic companies that were able to adapt and are now on the upswing. The top diagnostic stock to put on your radar is Exact Sciences (NASDAQ: EXAS). Most investors will recognize their at-home cancer screening kit is called cologuard which tests for colon cancer. Those primetime commercials you’ve likely heard mean they’ve established their brand along with a national audience. Testing volume dropped measurably during the pandemic as early cancer screening was pushed aside, but now their testing volumes are ramping back up and helping chew through the testing backlog created by the pandemic. It has taken a couple of years for EXAS testing volumes to return to pre-pandemic levels. In Q2 2024 the company had a record 1.0 million screenings and got back on its growth trajectory, helped by an expansion of cancer indications that include breast, prostate, and colon cancer. It also started its pipeline expansion into precision oncology. EXAS also made a move into a blood-based multi-cancer space when they purchased Thrive Early Detection Corp. for $2.15 billion. This purchase turned into a business vertical that not only does a deeper dive into the hereditary nature of the cancer but also profiles the tumor in such a way that it assists in the optimization of treatment regimens. The company has $2.6 billion in trailing revenues and a current market cap of $10.3 billion and is an overall leader in the diagnostic sector with solid earnings and a balance sheet for risk averse shareholders looking for a solid return from a company that consistently beats expectations. Guardant Health Inc. (NASDAQ: GH) has the first FDA-approved primary screening blood test for colorectal cancer (CRC). The test is called Shield and it is covered under the Medicare reimbursement program. Shield has a sensitivity of 83% and a 90% specificity (false positives) for advanced neoplasia (polyps that could turn cancerous). The company has $600 million in trailing revenues and a current market cap of $4.0 billion. They call it a non-invasive test, but you still have to get pricked. Another way to play the diagnostic market is to look at the top industry suppliers. llumina Inc. (NASDAQ: ILMN) is a medtech company that makes genetic testing equipment that enables the large-scale analysis of genetic variations. The company manufactures next-generation sequencing (NGS) platforms, microarrays, and bioinformatics software. Their machines are used in genomics research, clinical applications, and molecular diagnostics, which means their customers are research centers, pharma companies, academic institutions, and clinical research organizations. The company recently spun off their diagnostics business called Grail Inc. (NASDAQ: GRAL) which is an early cancer screening company for people that are not symptomatic, enabling a proactive approach to diagnosing cancer earlier. ILMN funded GRAL with a one-time cash payment of $923 million. The company's leading product is a multi-cancer early detection blood test called Galleri. The test screens for 50+ types of cancer by reading the DNA sequence. The backbone of the testing technology is from the Illumina platform and over 20,000 participants in large clinical trial studies. The test kits cost around $1100 each, and they are awaiting FDA approval for the test. Investors looking for a little more alpha should look at this diagnostic testing company disruptor and its game changing technology. Ludwig Enterprises Inc. (OTCMKTS: LUDG) is an exceptional OTC company in the diagnostic screening sector, boasting mRNA testing technology that has the potential to revolutionize the multibillion-dollar diagnostic screening industry with its less invasive tests. CEO Marvin S. Hausman MD stated, “mRNA is the language that interprets DNA and is the future of medicine.” Although the company currently has no revenue, it is gearing up for an exciting product launch in October, coinciding with Breast Cancer Awareness Month, which is expected to kickstart its revenue stream. To spearhead its viral marketing campaign, the company has enlisted a seasoned veteran. LUDG’s Lab Developed Test (LDT) will initially target breast cancer screening, but the technology can be easily adapted to other inflammatory-driven cancers. These LDTs are processed at the Genetics Institute of America, a CLIA lab, which allows for quicker product launches as they do not require FDA approval. The company has developed a unique cancer screening approach by measuring mRNA at the nucleotide level. Their test uses AI algorithms to create a personalized inflammatory index, comparing it to a database of over 3,200 mRNA samples collected from 40+ clinical centers over five years. This method, particularly for breast cancer, boasts a 97% test sensitivity, indicating when further evaluation is needed. The LUDG test kits will cost $249 and will follow proven successful direct-to-consumer viral marketing strategies driven by targeted machine learning algorithmic technologies. The CEO of LUDG Hausman has come out of retirement to lead this technology to commercialization. He is a Medical Doctor, Immunologist, and board certified Urological Surgeon. Investors in LUDG will have an experienced CEO at the helm with a proven track record of successful exits. One of his most notable exits was when he sold his NYSE company Medco Research to King Pharmaceuticals, which was ultimately acquired by Pfizer (NYSE: PFE). LUDG’s Revealia breast cancer test is very much like the EXAS Cologuard test. As investors move back into diagnostic stocks, these 4 represent a diversified basket every investor should put on their radar. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated to assist in the production and distribution of content related to LUDG. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Inc Mark McKelvie +1 585-301-7700 mark@razorpitch.com Company Website http://razorpitch.com

August 23, 2024 06:00 AM Eastern Daylight Time

1 ... 69 70 71 72 73 ... 3764